Back to Search Start Over

PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE

Authors :
S. Baffert
Marc Trossaert
B. Polack
C. Godard
Source :
Value in Health. 22:S846
Publication Year :
2019
Publisher :
Elsevier BV, 2019.

Subjects

Subjects :
Emicizumab
Pediatrics
medicine.medical_specialty
business.industry
Cost effectiveness
Health Policy
Haemophilia A
Public Health, Environmental and Occupational Health
Medicine
In patient
business
medicine.disease

Details

ISSN :
10983015
Volume :
22
Database :
OpenAIRE
Journal :
Value in Health
Accession number :
edsair.doi...........772ab1a7e91a78db0dee000a2872ee48

Tools

Authors Abstract Subjects Details